Co announces FDA and European CE Mark approvals to expand the capabilities of its Frontier II cardiac resynchronization therapy pacemaker to include QuickOpt Timing Cycle Optimization, giving ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results